How to access rituximab from India for MS, off-label use, the named-patient import pathway, 2026
By Reserve Meds · Clinical and regulatory team · Last reviewed 2026-06-04
Quick orientation
An Indian patient with relapsing multiple sclerosis (MS) may receive a prescription for rituximab (originator: Rituxan in the US, MabThera outside the US, both marketed by Genentech / Roche; biosimilars include Truxima, Ruxience, and Riabni) from their treating neurologist. Rituximab is not FDA-approved for MS. Its use in multiple sclerosis is off-label, but it is one of the most-used anti-CD20 therapies for MS globally, with the original randomised evidence from the HERMES trial (Hauser SL et al., N Engl J Med 2008;358(7):676-688) and decades of Scandinavian real-world cohort data. In India, rituximab is registered for several oncology and rheumatology indications and is available through local supply chains; CDSCO-administered named-patient import remains the standard pathway when a specific US-sourced originator product or a particular biosimilar lineage is required with full DSCSA chain-of-custody.
This guide explains the pathway, the off-label disclosure, the FDA Boxed Warning, documentation your physician prepares, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Rituximab is a chimeric (mouse-human) anti-CD20 monoclonal antibody that depletes B cells. It is administered as an intravenous (IV) infusion. For multiple sclerosis (off-label) the most common induction regimen is 1000 mg IV on Day 1 and Day 15, then maintenance with 500 to 1000 mg every six months, although several published protocols and Scandinavian centres use lower maintenance doses (500 mg q6 months or even q12 months once B-cell depletion is established). Your neurologist selects the regimen based on disease activity, prior DMT history, and centre experience.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Eligibility requires a confirmed relapsing MS diagnosis per McDonald criteria, MRI evidence, and a clinical rationale for off-label anti-CD20 therapy with rituximab specifically rather than an FDA-approved alternative (Ocrevus, Kesimpta, Briumvi). Before the first infusion, your neurologist will screen for active or chronic hepatitis B (HBsAg and anti-HBc), update vaccinations (including live vaccines before B-cell depletion), assess baseline serum immunoglobulins (IgG, IgA, IgM), and screen for active infection. Indian patients should also be screened with a lower threshold for tuberculosis given background prevalence. During therapy, immunoglobulin and infection surveillance continues at scheduled intervals; premedication with corticosteroid and antihistamine before each infusion is standard.
Off-label status for MS - what this means for the patient
Rituximab is FDA-approved for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (with methotrexate), granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris. It is not FDA-approved for multiple sclerosis. Use in MS is therefore off-label. Off-label prescribing of an FDA-approved medicine is a legal clinical decision made by a treating physician when the physician judges that the off-label use is supported by adequate evidence and serves the patient's interest. For rituximab in MS, the original randomised evidence is the HERMES trial (Hauser SL et al., N Engl J Med 2008;358(7):676-688), with subsequent large real-world cohort data, particularly from the Swedish MS registry, supporting efficacy comparable to FDA-approved anti-CD20 therapies at substantially lower cost. The European Academy of Neurology and the Multiple Sclerosis International Federation recognise rituximab as a B-cell-depleting option for MS where access to FDA-approved alternatives is limited.
For an Indian patient, the practical consequence of off-label status is that the treating neurologist's clinical rationale and informed-consent documentation must explicitly acknowledge off-label use and document the reasoning. Reserve Meds includes off-label disclosure templates in the physician documentation kit.
Why Indian patients route via the named-patient pathway
Rituximab is locally registered in India through several marketing-authorisation holders for oncology and rheumatology indications, and domestic supply is the simplest route in many cases. CDSCO-administered named-patient import becomes the right pathway when (a) the treating neurologist or patient specifies US-sourced originator Rituxan or US-sourced MabThera for chain-of-custody assurance, (b) a specific biosimilar lineage from the US originator (Truxima, Ruxience, or Riabni) is preferred, or (c) the patient requires DSCSA-tracked supply to satisfy a treating-physician or family documentation standard. The CDSCO personal-import / named-patient framework administered under the Drugs and Cosmetics Rules permits import for a specific named patient when the medicine is approved by a recognised reference authority such as the US FDA, no clinically equivalent locally registered alternative is suitable, a qualified Indian physician accepts clinical responsibility, and chain of custody is documented.
How the pathway works, step by step
- Consultation with your treating neurologist. Confirmation of MS subtype, MRI review, prior disease-modifying therapy (DMT) history, and clinical rationale for off-label anti-CD20 therapy with rituximab. Informed consent acknowledging off-label MS use and the FDA Boxed Warning.
- Pre-treatment screening. Hepatitis B panel (HBsAg and anti-HBc total), baseline serum immunoglobulins (IgG, IgA, IgM), vaccination review with update of live vaccines before depletion, an active-infection screen, and tuberculosis screening where clinically indicated.
- Infusion facility identification. A licensed infusion centre is confirmed for the Day 1 and Day 15 induction infusions and subsequent six-monthly maintenance cycles.
- CDSCO named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, off-label MS use acknowledgement, patient reference, product details (originator versus specific biosimilar), and a chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure US-sourced Rituxan or the requested biosimilar from authorised distribution under DSCSA.
- Cold-chain shipment. Rituximab ships under validated 2-8 degrees C cold chain with continuous temperature logging and chain-of-custody documentation.
- Arrival and administration. The infusion facility receives the vials and schedules infusions under your neurologist's care with full Boxed Warning premedication protocol.
Where rituximab is administered in India
MS-experienced neurology programmes that have run named-patient anti-CD20 cases, and that have established infusion-centre and post-infusion monitoring protocols, include Apollo (Chennai, Hyderabad, Delhi), Tata Memorial-associated neurology referrals (Mumbai), AIIMS (New Delhi), Christian Medical College (CMC) Vellore, Max Healthcare (Delhi NCR, Saket and Patparganj), Kokilaben Dhirubhai Ambani Hospital (Mumbai), Medanta The Medicity (Gurgaon), Fortis Memorial Research Institute (Gurgaon, Mulund, Anandapur), and Manipal Hospitals (Bengaluru, Jaipur, Pune). Many of these centres already infuse rituximab routinely for oncology and rheumatology indications, so MS off-label administration uses the existing infusion-centre infrastructure. Your neurologist confirms the suitable facility based on monitoring capability for infusion reactions and post-infusion review.
What documentation your physician needs to provide
- Clinical rationale letter confirming relapsing MS subtype and rituximab as the indicated off-label therapy, with explanation of why rituximab is preferred over the FDA-approved anti-CD20 alternatives (Ocrevus, Kesimpta, Briumvi)
- Off-label informed-consent document signed by the patient acknowledging off-label MS use and the FDA Boxed Warning
- Verification of Indian medical registration (NMC or state medical council)
- MRI report supporting the diagnosis
- Hepatitis B screening results (HBsAg, anti-HBc) and vaccination history
- Baseline immunoglobulin levels (IgG, IgA, IgM)
- Tuberculosis screening where clinically indicated
- Identification of the administering infusion facility
- Planned dosing calendar (1000 mg IV Day 1 and Day 15 induction; 500 to 1000 mg IV q6 months maintenance, or centre-specific protocol)
- Monitoring plan (immunoglobulins, infection surveillance, neurological re-evaluation cadence)
Reserve Meds provides a physician documentation kit bundling templates CDSCO reviewers expect for anti-CD20 MS named-patient imports, including the off-label disclosure and the Boxed Warning informed-consent document.
Real cost picture
US WAC reference for originator Rituxan is approximately USD 1,000 to 1,200 per 100 mg vial (Genentech IR; US specialty-pharmacy WAC reporting via Drugs.com and GoodRx). A 500 mg dose therefore costs approximately USD 5,000 to 6,000 in originator at WAC, and a 1000 mg dose approximately USD 10,000 to 12,000. Indicative annual MS-protocol cost at originator WAC, after the induction year, runs in the range of USD 9,000 to 16,000 depending on whether the centre uses a 500 mg q6 months or 1000 mg q6 months maintenance regimen. US cash-pay specialty-pharmacy networks transact at lower negotiated rates. Biosimilar products (Truxima, Ruxience, Riabni), when available through our US specialty wholesale partner, transact at meaningfully lower price points and are often the preferred choice for cost-sensitive MS courses. Cold-chain international logistics, CDSCO documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a transparent itemised quote at the start of intake comparing originator and biosimilar options; these figures are indicative drug-only reference pricing, not the delivered total.
Indicative timing for first infusion after cohort intake opens is 7 to 14 days from the moment a complete CDSCO application is submitted. Subsequent six-monthly maintenance cycles are generally faster once the pathway is established.
If your clinical situation is time-sensitive, tell us at intake. We triage accordingly.
What to monitor on rituximab
Rituximab sits in the anti-CD20 class with Ocrevus (ocrelizumab), Briumvi (ublituximab), and Kesimpta (ofatumumab). Because rituximab carries the FDA Boxed Warning summarised above and is the oldest and most-used drug in the class, the safety profile is the best characterised. Four safety signals, all named in the Boxed Warning or the Warnings and Precautions section, govern monitoring for an Indian MS patient on off-label rituximab: severe infusion reactions, hepatitis B virus reactivation, progressive multifocal leukoencephalopathy, and persistent hypogammaglobulinaemia. Each is described below with monitoring cadence and prescribing-information citation.
Severe infusion reactions and mucocutaneous reactions. The Rituxan Boxed Warning describes severe and sometimes fatal infusion reactions, most often during or within 24 hours of the first infusion, with approximately 80 percent of fatal infusion reactions in the post-marketing setting occurring on the first infusion (Rituxan Prescribing Information, Boxed Warning and section 5.1). Premedication with corticosteroid, antihistamine, and antipyretic is standard before each infusion. The first infusion is given slowly with continuous observation; subsequent infusions can be given faster once initial tolerability is established. Severe mucocutaneous reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported, with most cases occurring between 1 and 13 weeks after the first dose (Rituxan Prescribing Information, Boxed Warning and section 5.2). Any rash, blistering, or mucosal involvement warrants immediate discontinuation and dermatology evaluation. Reference: Rituxan Prescribing Information, Boxed Warning sections 1 and 2; sections 5.1 and 5.2.
Hepatitis B virus reactivation. The Rituxan Boxed Warning highlights HBV reactivation, including fulminant hepatitis, hepatic failure, and death, in patients receiving rituximab (Rituxan Prescribing Information, Boxed Warning and section 5.3). Pre-treatment screening for HBsAg and anti-HBc is mandatory before the first dose. Patients with chronic hepatitis B (HBsAg-positive) or resolved hepatitis B (anti-HBc-positive, HBsAg-negative) require hepatology co-management; antiviral prophylaxis with entecavir or tenofovir is standard for chronic carriers and is often used for resolved-infection patients on rituximab. Monitoring of HBV DNA and liver enzymes continues during and for several months after the last rituximab dose. Given higher background prevalence of chronic hepatitis B in parts of India, this screening and the prophylaxis plan are particularly important. Reference: Rituxan Prescribing Information, Boxed Warning section 3; section 5.3.
Progressive multifocal leukoencephalopathy (PML) and JC virus. The Rituxan Boxed Warning includes PML, a rare and often fatal brain infection caused by reactivation of the JC virus in immunosuppressed patients (Rituxan Prescribing Information, Boxed Warning and section 5.4). PML cases have been reported in patients receiving rituximab for haematologic malignancy, rheumatologic disease, and autoimmune indications including MS. Baseline JC virus antibody serology is not mandated by the FDA label before initiation but is often obtained for risk stratification, particularly when sequencing onto rituximab from natalizumab (Tysabri). Any new neurological symptom during treatment, including symptoms that do not fit the patient's prior MS relapse pattern, warrants urgent neurology re-evaluation with MRI. Reference: Rituxan Prescribing Information, Boxed Warning section 4; section 5.4.
Hypogammaglobulinaemia and immunoglobulin monitoring. Anti-CD20 monoclonal antibodies deplete B-lymphocytes and, with repeated dosing, reduce circulating immunoglobulin levels over time. The Rituxan label calls for measurement of quantitative serum immunoglobulins before initiation, periodically during treatment, and after discontinuation until B-cell repletion (Rituxan Prescribing Information, section 5.7 in the rheumatology and granulomatosis-with-polyangiitis sections). MS-experienced Indian centres typically check IgG, IgA, and IgM at baseline and every six months at the maintenance-infusion visit. Persistent hypogammaglobulinaemia, particularly IgG below 4 g/L, increases the risk of serious bacterial infection; immunoglobulin replacement (IVIG) may be considered in consultation with immunology if levels remain low and infections recur. References: Rituxan Prescribing Information, section 5.7; Hauser SL et al., HERMES trial, N Engl J Med 2008;358(7):676-688.
Frequently asked
Is this legal in India? Yes, when executed through the CDSCO named-patient / personal-import framework with appropriate documentation, off-label disclosure, and a licensed administering facility. Rituximab is also locally registered in India for several non-MS indications, so domestic supply is an alternative pathway. See our trust and compliance page.
Is rituximab FDA-approved for MS? No. Rituximab is FDA-approved for non-Hodgkin lymphoma, chronic lymphocytic leukaemia, rheumatoid arthritis (with methotrexate), granulomatosis with polyangiitis, microscopic polyangiitis, and pemphigus vulgaris. Use of rituximab for MS is off-label.
Why is rituximab used off-label for MS when FDA-approved anti-CD20 alternatives exist? Cost is the main reason globally. Rituximab predates the FDA-approved anti-CD20 MS therapies (Ocrevus 2017, Kesimpta 2020, Briumvi 2022) and has decades of real-world MS data, particularly from Sweden. Many neurologists internationally select rituximab for MS where the FDA-approved alternatives are unaffordable or unavailable. The decision is made by the treating neurologist after weighing efficacy, safety, cost, and availability.
How does rituximab compare with Ocrevus, Kesimpta, or Briumvi? All four are anti-CD20 therapies. Rituximab is IV, given as induction then six-monthly (or longer interval) maintenance; Ocrevus is six-monthly IV; Briumvi is IV with shorter infusion times; Kesimpta is monthly subcutaneous self-injection. Rituximab has the longest track record and the broadest real-world data set but is the only one not FDA-approved for MS.
Originator Rituxan or biosimilar? Both are options. The treating neurologist and the patient decide based on cost, supply, and centre experience. Reserve Meds quotes originator and biosimilar side-by-side at intake. Once a patient starts on a specific product (originator versus a particular biosimilar), maintenance cycles typically continue on the same product unless the neurologist directs a change.
Why hepatitis B screening? Hepatitis B reactivation is named in the Rituxan Boxed Warning. Pre-treatment HBsAg and anti-HBc screening is mandatory under FDA labeling, and antiviral prophylaxis is required for chronic carriers and often used for resolved-infection patients.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers reimburse rituximab for on-label indications (lymphoma, rheumatoid arthritis) but rarely for off-label MS use. Reserve Meds supplies documentation but does not process claims directly.
Recent regulatory and access news for rituximab in India
The CDSCO Notifications feed at cdsco.gov.in/Notifications has not posted a rituximab-specific MS-indication notification over the last 12 months as of 2026-06-04. Rituximab remains registered in India under multiple originator and biosimilar marketing authorisations for non-MS indications. The Drugs Controller General of India has not added a rituximab-for-MS approval to the Approved New Drugs list at cdsco.gov.in Approved-New-Drugs. The National Pharmaceutical Pricing Authority database at nppaindia.nic.in and the Pharmacovigilance Programme of India at ipc.gov.in continue to monitor rituximab safety signals across all uses. The European Academy of Neurology and the Multiple Sclerosis International Federation continue to recognise rituximab as a B-cell-depleting option for MS where access to FDA-approved alternatives is limited. We update this section on each case file at intake; the snapshot date governs.
Reserve Meds role
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody. Originator Rituxan or biosimilar (Truxima, Ruxience, Riabni) as your neurologist directs.
- Documentation. Regulatory package for your physician and CDSCO review, including the off-label MS disclosure and Boxed Warning informed-consent templates.
- Logistics. Validated cold-chain shipment to your prescribing infusion facility.
- Concierge case lead. A named point of contact coordinating each six-monthly cycle.
What we do not do: we are not the prescriber, do not practise medicine, and are not the dispensing pharmacy. All clinical decisions, including the decision to use rituximab off-label for MS, remain with your treating neurologist and the administering infusion facility.
Next step
Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines. Rituximab use in MS is off-label and carries an FDA Boxed Warning that the prescribing physician must discuss before initiation.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are not a pharmacy, not the prescriber, and not the manufacturer. Cash-pay. Export-only (US to overseas). Composite case examples. Not medical advice.
Clinical and regulatory review: Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last medically reviewed: 2026-06-04.